MYCN deregulation is a recognized driver for numerous childhood and adulthood neuronal and nonneuronal tumors including neuroblastoma, medulloblastomas, rhabdomyosarcoma, neuro-endocrine prostate cancer, Wilms tumor, lymphoma and AML [1]. Here, MYCN is linked to medulloblastoma.